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ABSTRACT
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and North-
American algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. 
Methods: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the 
latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance 
programs for each of the eight countries represented at the Forum were also analyzed. Results: A specific set of guidelines based 
upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also 
discussed. Conclusions: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be 
adapted to our region directly from purely European and North-American guidelines for treatment.
Key words: multiple sclerosis, treatment, Latin America. 
RESUMO
Objetivo: Estima-se que haja aproximadamente 50.000 pessoas com a forma remitente-recorrente da esclerose múltipla na América 
Latina. Os algoritmos de tratamento norte-americanos e europeus não levam em consideração nossas peculiaridades regionais, nem a 
dificuldade no acesso ao tratamento por parte dos pacientes. Métodos: O Fórum Latino-americano de Esclerose Múltipla é um grupo de 
especialistas independente e suprainstitucional, que avaliou as mais recentes evidências científicas sobre a eficácia e a segurança das 
drogas modificadoras do curso da doença. Foram avaliados também o acesso ao tratamento e os programas de farmacovigilância de cada 
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Multiple sclerosis (MS) treatment in Latin America is a 
dynamic process due to the approval of new drugs world-
wide, with particular emphasis on oral drugs at this moment. 
The introduction of these drugs in Latin American coun-
tries tends to be gradual, using data from local pharmaco-
vigilance programs and often based on studies carried out in 
other continents. The potential patient population in the re-
gion presenting relapsing-remitting MS (RRMS) is estimated 
to be of the order of 50,000 people1, while its prevalence varies 
between 1.48 and 25 per 100, 000 inhabitants2-8. The main ob-
jectives of the present study were to update the therapeutic 
algorithm designed in 20109 and to assess the use of medica-
tions in several countries of the region. The present study fo-
cused on the first, second, and third-line therapeutic options, 
while a detailed and updated discussion on MS diagnosis can 
be found elsewhere10.
A literature search was carried out at PubMed database, 
using the key words ‘multiple sclerosis’, ‘relapsing-remitting’, 
‘drug therapy’, ‘disease-modifying drugs’, and the internation-
ally recognized name of each individual compound. More re-
cent papers and systematic reviews with solid levels of evi-
dence were selected by the group. Studies involving Latin 
American populations were also included.
Since 2009, the Latin American MS Forum has been 
meeting annually with the intention of analyzing the lat-
est advances in MS management. The 2011 meeting took 
place in Brazil and included a panel of 12 independent neu-
rologists, with experience in MS. These experts were from 
Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uruguay, 
and Venezuela. Based on the selected papers, the available 
level of evidence of each disease-modifying drug was an-
alyzed regarding efficacy and safety. Additionally, health 
system coverage of expenditure on drugs and pharmaco-
vigilance programs was assessed in individual countries. 
Drugs under analysis for approval and generic medica-
tions without scientific evidence were also discussed. The 
panel also took into consideration treatment of children 
with MS. It was agreed that a recommendation would be 
considered to be ‘approved’ when at least 10 out of the 12 
experts (83.3%) accepted it.
DISEASE-MODIFYING DRUGS
RRMS treatment is based on different therapeutic lines, 
which are classified according to the available evidence re-
garding use, efficacy, and toxicity of medications. The first line 
of therapy comprises Glatiramer Acetate and Interferon-beta. 
The second one includes Natalizumab and Fingolimod. In case 
of further therapeutic failure, treatment progresses to a third 
line, represented by Rituximab and Alemtuzumab. The fourth 
line includes bone marrow transplantation and high doses of 
cyclophosphamide. Figure presents the treatment algorithm 
proposed for Latin America. In addition to the abovemen-
tioned drugs, a review on Mitoxantrone, Methotrexate, and 
Azathioprine has also been conducted in order to make rec-
ommendations for their use in Latin America, while several as-
pects regarding generic medications have also been discussed.
FIRST LINE OF TREATMENT
Glatiramer Acetate and Interferon-beta (low or high dos-
es) are the first line of treatment options. Their efficacy and 
safety are well established and can be found in other sourc-
es9. Patients initially treated with low-dose interferon that 
present therapeutic failure must be switched to glatiramer 
acetate. Patients initially treated with glatiramer acetate that 
present therapeutic failure must be switched to high-dose in-
terferon. There is no evidence supporting a switch between 
low and high doses of interferon11.
SECOND LINE OF TREATMENT
The second line comprises Natalizumab and Fingolimod. 
There is no evidence allowing recommendation of one drug 
over the other.
Use of Natalizumab is supported by level I evidence. In 
all countries belonging to this forum, the drug has been ap-
proved or is undergoing approval. Its efficacy and anti-in-
flammatory activity translate into a significant decrease 
in relapse rates and disability (measured on the Expanded 
Disability Status Scale — EDSS), as well as a decrease in gad-
olinium-enhancing lesions and new ones, as assessed using 
magnetic resonance imaging (MRI)12,13. Safety measures in-
clude serum assessment of JC virus (debatable importance), 
MRI (not less than three months before drug infusion — 
baseline), chest radiography, blood cell count (before each 
infusion, requiring neutrophils above 1,500/mm3 and lym-
phocytes above 1,000/mm3), and lymphocyte CD4/CD8 phe-
notype every three months. 
The most serious complication of this drug treatment is the 
development of progressive multifocal leukoencephalopathy 
um dos oito países representados no Fórum. Resultados: Uma lista específica de recomendações baseadas em evidências científicas foi 
estabelecida para a América Latina. Também foram discutidas perspectivas de futuros tratamentos para esclerose múltipla. Conclusões: 
O presente estudo representou um esforço dos representantes de oito países latino-americanos em discutir um assunto que não pode ser 
adaptado para uso em nossa região diretamente a partir de recomendações de tratamento europeias ou norte-americanas.
Palavras-Chave: esclerose múltipla, tratamento, América Latina.
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(PML), with a risk that increases considerably after two years 
of continuous treatment14-16. At present, there are no bio-
markers preceding the development of PML, and no evidence 
allowing recommendations to be made for a stabilized pa-
tient after a period of Natalizumab treatment (i.e., to contin-
ue with natalizumab or to return to a first-line therapeutic 
option). This decision must be based on each individual case. 
The experts highlighted the importance of making the risks 
clear to patients, if treatment with Natalizumab is to be con-
tinued, and suggested that a new informed consent should 
be signed by all parties. 
One important precaution is to administer the drug at 
a recognized infusion center, with continuous monitoring 
by a certified doctor throughout the period of infusion (in 
Argentina and Brazil, the recommendation is to have immedi-
ate access to a cardiac defibrillator during infusion). Drug ad-
ministration must be made on a regular basis (Natalizumab 
300 mg by means of intravenous infusion every 28 days). If 
the patient presents any clinical changes leading to suspect-
ed relapse of PML, MRI should be performed. A washout pe-
riod must be observed prior to natalizumab treatment, with 
at least a six-month interval if the patient has received any 
previous oral immunosuppressive drugs, and a one-year in-
terval if he/she has previously been treated with intravenous 
immunosuppressive drugs. Natalizumab is not recommend-
ed for patients with positive serum tests for HIV and HTLV 
(Human T lymphotropic virus) viruses or with active tuber-
culosis, or for those who have at any time been treated with 
Rituximab. The countries represented in the Forum have ad-
opted different pharmacovigilance programs for this drug: in 
Argentina, there is monitoring of prescriptions, in Colombia 
and Venezuela, there is a Technical Assistance Program for 
Tysabri® Prescribers (PATTY); while Mexico and Brazil are 
monitoring its use by their own national health programs.
Fingolimod was approved by the Food and Drug 
Administration (FDA) as a first-line treatment; however this 
is controversial due to the serious side effects that have been 
reported when using this drug. Due to the lack of long-term 
safety data, the experts recommend that fingolimod should 
be used as a second-line option when there is therapeutic 
failure with Glatiramer Acetate or Interferon-beta, or for pa-
tients with very active and aggressive MS or those with rap-
idly progressing disease. Use of Fingolimod is supported by 
level I evidence, published data shows that oral Fingolimod 
0.5 mg/day reduced the relapse rates, as well as the new le-
sions and gadolinium-enhancing new lesions on MRI17,18. The 
main adverse events with this drug are cardiac (severe brady-
cardia and atrioventricular block), meaning that the patients 
need close cardiac monitoring following the first drug admin-
istration, and periodic monitoring thereafter19. The patient’s 
follow-up must include periodic ophthalmological monitor-
ing ( for macular edema) and dermatological assessments ( for 
Glatiramer
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Figure. Latin American treatment algorithm for relapsing-remitting multiple sclerosis and for clinically isolated syndrome, in 2011.
aThere are no comparative studies allowing selection of one or another second-line drug; bif treatment with natalizumab is to be continued, the recommendation 
is to obtain a new informed consent; RRMS: relapsing-remitting multiple sclerosis; IFN: interferon; BM: bone marrow; CIS: clinically isolated syndrome.
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varicella and herpes infections). Among the additional precau-
tions necessary during this treatment, pregnancy must be re-
ported to pharmacovigilance programs, since the drug must 
be withdrawn, and vaccination with live attenuated organ-
isms should be avoided. In the majority of countries represent-
ed in this Forum, Fingolimod is undergoing approval and no 
specific pharmacovigilance programs have been designed. In 
Argentina, this drug is controlled by the Risk Evaluation and 
Mitigation Strategy (REMS) pharmacovigilance program. 
THIRD LINE OF TREATMENT
Alemtuzumab is approved in several Latin American 
countries for treatment of hematological diseases, but its in-
dication for MS still awaits results from phase III clinical tri-
als. Its use as a third-option drug for very aggressive RRMS is 
supported by level I evidence, with reports presenting relapse 
rate reduction, decreased brain atrophy measurements, and 
EDSS improvement20,21. The recommended dose is from 12 to 
24 mg/day administered by means of intravenous infusion, 
requiring two to three infusions per year. The precautions for 
use of Alemtuzumab are similar to the abovementioned ones 
for Natalizumab22. The main adverse event related to this 
drug is autoimmune disease (thrombocytopenic purpura, 
hyperthyroidism, hypothyroidism, and thyroiditis). The med-
ication has not yet been approved for use in MS and, there-
fore, there are no specific implemented programs for phar-
macovigilance, although they are to be expected.
Rituximab is approved in all countries represented in the 
Forum for diseases other than MS (hematological diseases and 
rheumatoid arthritis)9, and its use in MS is justifiable only in iso-
lated cases23. The recommended dose is two pulses of 1,000 mg/
day administered by means of intravenous infusion on days 0 
and 15. The cycle should be repeated after six months 24. This 
drug must not be prescribed for HIV-positive patients. 
USE OF OTHER DRUGS IN SPECIAL SITUATIONS
Mitoxantrone is approved in the majority of the countries 
represented in the Forum and has been used as an induction 
treatment for very aggressive MS (non-responsive, rapidly pro-
gressive, secondary progressive and very active MS), prior to 
treatment with first-line drugs25. In these cases, this drug re-
duces relapse rates and the disability assessed by the EDSS 
score, thereby delaying disease progression. Its efficacy is sup-
ported by level I evidence26. MRI shows a reduction in the 
number of new lesions and new gadolinium-enhancing ones27. 
Several studies have shown beneficial effects in the sec-
ondary progressive form of the disease, although the ther-
apeutic schemes used in them have varied considerably, 
thus making it particularly difficult to compare data among 
different studies28-30. Risks associated with Mitoxantrone 
treatment include the development of leukemia, cardiotox-
icity (12 to 25% of the cases), and infections if the dose ex-
ceeds 60 mg/m2. However, the latter cannot be taken as an 
absolute statement, since the dose must be determined in-
dividually, according to the patient’s characteristics, the dis-
ease itself, and previous treatments. For example, adminis-
tration of Methylprednisolone may mask the development 
of cardiotoxicity. This toxicity and the different criteria used 
to define ‘very aggressive’ and ‘very active’ forms of MS have 
severely limited use of this drug for rescue therapy in some 
countries31-34, but the Forum does not recommend its use 
in a regular manner. Strict cardiological follow-up must be 
carried out for further two years beyond the end of therapy, 
including echocardiography, assessment of ventricular ejec-
tion fraction, and cardiac Holter. The monitoring should also 
include blood cell counts on a regular basis for at least two 
years after the drug has been suspended, and cases of leuke-
mia must be notified. Use of Mitoxantrone is subject to each 
country’s national pharmacovigilance program.
Methotrexate has different recommendations in the coun-
tries represented in the Forum. While in Argentina it is used 
solely as part of combined therapies for non-responsive pa-
tients, some neurologists in Brazil may use this drug for no 
longer than two years (consecutive or with interruptions), al-
though the Brazilian protocol does not include this drug for MS 
treatment. Use of Methotrexate for MS is supported by level IV 
evidence. The medication has been approved and is available 
in all countries of the Forum. A literature review on this drug35 
showed that it presents considerable adverse events with the 
recommended 7.5 mg/week dose, while no significant thera-
peutic effect can be observed in relation to placebo or other 
medications36. Therefore, the Forum does not recommend us-
ing methotrexate for MS. The experts highlighted that, if the 
drug is to be used at all, fertile female patients must use effi-
cient contraceptive methods. In the Latin American countries 
represented in the Forum, use of this drug is subject to the in-
dividual national pharmacovigilance program.
Administration of Azathioprine has been approved in 
all countries in this Forum, although there are differences 
in its recommendations. In Argentina and Colombia, it is 
used for RRMS patients undergoing combined therapy (as-
sociated with low-dose interferon) as a third-line treatment. 
In Colombia, the recommendation from the Colombian 
Neurological Society37 is to maintain this treatment for no 
longer than two years. In Brazil, azathioprine is an option 
for patients who cannot tolerate injectable drugs; while in 
Chile and Uruguay, it is used as a second-line therapy. In 
Mexico and Peru this drug is used for secondary progres-
sive MS or for patients with very active disease (in Peru it is 
also used if patients do not have access to immunomodula-
tory drugs); and in Venezuela, it is not recommended at all. 
There are few systematic reviews regarding the efficacy and 
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safety of azathioprine and its use is based on level II evidence 
and type C recommendation38-40. Based upon these data, the 
Forum does not recommend use of azathioprine in a system-
atic manner and, if the drug is to be used, then clinical and 
laboratorial monitoring (blood cell count and liver function) 
must be performed every three to six months. Regarding 
pharmacovigilance on azathioprine, all countries use their 
general national program for it.
Cyclophosphamide is recommended as a rescue thera-
py in RRMS cases that are resistant to previously discussed 
treatments, as well as in rapidly progressive or ‘very active’ 
MS, or in those in which the patient has poor prognosis. The 
2007 Cochrane review41,42 showed that, in general, the pub-
lished studies are limited to small groups of patients, and 
very few trials have followed the recommendations for ran-
domization, double-blinding and placebo control, thus giv-
ing the drug level II evidence, with type C recommendation. 
With the exception of the previously mentioned situations, 
the Forum does not recommend cyclophosphamide, because 
of its severe adverse effects, which include sepsis (including 
five recorded cases of death), alopecia, amenorrhea and cys-
titis43, and neutrophil ablation44,45. 
The experts advised against use of generic medications 
due to the lack of data supporting their bioequivalence and 
bioavailability. Furthermore, it is not possible to establish the 
efficacy and safety of generic medications available in some 
countries represented in the Forum (Argentina, Mexico, Peru, 
and Uruguay), since there are no published papers in indexed 
journals. Considering the ever-growing availability of these 
products in Latin America and for political and administra-
tive issues relating to approval of these drugs, the experts 
highlighted risks involved in the indiscriminate use of origi-
nal and generic medications for treating patients with MS.
PHARMACOVIGILANCE SYSTEMS AND MULTIPLE 
SCLEROSIS TREATMENT COVERAGE IN LATIN AMERICA
Each country presented their pharmacovigilance sys-
tems and coverage programs for expenditures relating to MS 
treatment (Table 1).
Being aware of new drugs development and of the impor-
tance of seeking comprehensive and trustworthy pharmaco-
vigilance data, the Forum proposed that a supranational da-
tabase with information on drug safety and efficacy should 
be created, with the aim of long-term data collection.
PEDIATRIC MULTIPLE SCLEROSIS 
Although a relatively rare condition, pediatric MS 
(Ped-MS) is important because of its impact on a stage of 
life involving growth and development. It may represent 
up to 10% of MS cases. In general, it is manifested as RRMS 
with a higher relapse rate than that observed in adult pa-
tients. However, at present, there are no data on clinical 
trials carried out with disease-modifying agents among 
children and adolescents with MS that could provide level 
America, according to country, in 2011.
MS: multiple sclerosis; RRMS: remitting-relapsing multiple sclerosis; ANMAT: Drug, Food and Medical Technology Administration; ANVISA: National Agency for 
Sanitary Vigilance; CENIMEF: National Database Center for Drugs and Pharmacovigilance; COFEPRIS: Federal Committee for Protection Against Sanitary Risks; 
DIGEMID: General Direction for Medications, Supplies, and Drugs; PATTY: Technical Assistance Program for Tysabri® Prescribers; RIPS: Individual Registration 
for the Health Service; CIS: clinically isolated syndrome; SP: Secondary Progressive MS; aThe Peruvian Health System cares for 60% of the population in the 
country, but does not cover MS treatment.
Country Covered population Source of coverage Pharmacovigilance program
Argentina Total Public SystemPrivate System
Optional information from doctors and compulsory ones 
from the pharmaceutical industry to ANMAT; special 
natalizumab program developed for the country by the 
pharmaceutical company.
Brazil Total Public Health System National program for reporting adverse events (ANVISA).
Chile Total Plan for Specific Health Guarantees
National program carried out by CENIMEF. There is no 
compulsory reporting.
It is foreseen that special programs for recently developed 
drugs (natalizumab, fingolimod) will be implemented.
Colombia Total Law 100, Compulsory Health from the Social Security Institute
National program (RIPS).
PATTY program for natalizumab.
Mexico
~80% of all patients 
with RRMS (not for 
SPMS)
Social Security National program (COFEPRIS).
Perua
25% Social Security (clinically defined forms of MS, no CIS) Adverse events reported by the pharmaceutical industry 
to the National Pharmacovigilance Service at DIGEMID.
A special program for natalizumab is envisaged.2% Military and police personnel (RRMS)
10–15% Private System
Uruguay Total National Resource Funds National program (National Pharmacovigilance Center).
Venezuela
90% Venezuelan Institute of Social Security National program (National Pharmacovigilance Center).
PATTY program for natalizumab.10% Military Health
Table 1. Pharmacovigilance systems and expenditure coverage for drugs in Latin.
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I evidence46. The available evidence come from observa-
tional studies including case series47. In the absence of 
specific clinical trials regarding treatment of clinically iso-
lated syndrome (CIS) and RR disease in children and ado-
lescents, the treatment is based upon clinical experience 
and uses information from treatment of adults with MS46. 
None of the presently available disease-modifying agents 
for treating adults has been formally approved for treatment 
of children and adolescents46. However, the main choices are 
first-line treatments (one of the immunomodulatory drugs, 
i.e., interferon or glatiramer acetate), which appear to be safe 
and well tolerated in younger patients47. As is the case with 
adults, in Ped-MS it may be necessary to escalate the treat-
ment, but experience with second48,49, third50, and fourth51 
lines of therapy in children and adolescents is limited and 
based upon anecdotal evidence. 
The experts assessed the situation of pediatric patients 
in different countries, regarding specialists caring for these 
cases (general neurologists, pediatricians, and neuropediatri-
cians) and medications that are prescribed in daily practice. 
It was observed that in Argentina, Ped-MS is usually treat-
ed by neuropediatricians, although cities in its countryside 
may  not have such specialists, therefore general neurolo-
gists may treat them. The drugs used for these patients are 
interferon and glatiramer acetate. All immunomodulatory 
drugs accepted for adults were also approved for children in 
Brazil, where neurologists caring for adults with MS usually 
are also responsible for Ped-MS, unless there is a neuropedia-
trician in the group. The same medications used for adults 
are also recommended for Ped-MS in Colombia, but for those 
younger than 15 years of age and for those with weight lower 
than 40 kg, the recommendation is to start treatment using 
one third of the adult dose of interferon. 
Patients are cared for by neurologists who are special-
ists in MS, together with neuropediatricians. At the time 
of the present work, Chile had only eight reported cases of 
Ped-MS, all of them undergoing treatment with interferon. In 
Mexico, all cases of Ped-MS are treated by neuropediatricians 
(the majority of cases using Interferon-beta and a few cas-
es, Glatiramer Acetate). The few detected cases of Ped-MS in 
Peru were referred to general neuropediatricians or neurolo-
gists with experience in treating MS. There is no medication 
specifically approved for Peruvian children, but all detected 
cases are undergoing treatment with interferon. Pediatric pa-
tients in Uruguay are treated by neuropediatricians up to the 
age of 15 years, and by neurologists thereafter. The main pre-
scribed treatment is Interferon beta 1-b and, in lower propor-
tion, Interferon beta 1-a and Glatiramer Acetate. Treatment 
of pediatric cases in Venezuela (approximately 60 cases) is 
carried out by neuropediatricians, who prescribe all present 
available drugs. A recent case of Natalizumab treatment in 
a patient younger than 18 years-old was mentioned by the 
Venezuelan panelist.
NEW CONCEPTS AND THERAPEUTIC AIMS
The experts discussed new concepts relating to MS treat-
ment. Drugs developed more recently have made it possible 
to aim towards new therapeutic outcomes, such as reaching 
disease remission or having a patient classified as ‘free from 
disease activity’ (absence of relapses and of disability pro-
gression, with stable MRI)52. This concept was based on the 
possibility of establishing the disease activity level in a more 
trustworthy manner, measured using new MRI techniques 
( functional MRI and magnetic transference image). 
The panelists also highlighted the importance of corre-
lating the image with the clinical manifestations, including a 
neurocognitive assessment on MS patients. Even if the most 
used scale for measuring disease progression is EDSS, the MS 
Functional Composite was suggested to be always applied if 
the treatment unit has properly trained professionals, thus al-
lowing better assessment of cognitive deterioration. The Brief 
Repeatable Battery is another useful tool for assessing cogni-
tion, has been validated in Latin America53, and a variety of 
neuropsychological tests can be considered for patients’ as-
sessment54. It can be applied by neurologists specially trained 
for using it, and systematic use of this battery could help in 
screening cognitive decline. If necessary, the neurologist 
should refer the patient to a neuropsychologist for further test-
ing. The Mini-Mental State Examination, on the other hand, 
has no use for neurocognitive assessment of MS patients. 
Beyond neurocognitive testing, it was also recommended that 
regular assessment of quality of life should be made as part of 
the patients’ follow-up. For this purpose, the experts suggested 
that the MS Quality of Life Scale should be used, which is more 
specific than the Short Form (36) Health Survey (SF-36) .
The present work may have had some limitations. Part of 
the literature review used here is related to clinical trials car-
ried out mainly among European and North-American sub-
jects, who may have different epidemiological characteristics 
and comorbidities to those of a Latin American population. 
Even inside Latin America, there may be differences de-
pending on the abovementioned variables for each country. 
However, there are Latin American published papers that are 
not PubMed indexed and, therefore, their information may 
be underrepresented in our analysis. In accordance with the 
Forum objectives, the experts focused on the therapeutic as-
pects of MS in Latin America and did not discuss some general 
points, such as induction therapy, which is hardly ever used in 
the countries represented in this meeting. Lastly, some stud-
ies used here for assessing drug efficacy have methodological 
differences, which make it difficult to establish comparisons.
Decision-making in relation to RRMS is becoming more 
complex because of the growing availability of drugs and 
the lack of studies comparing them directly among each 
other. The experts have designed a therapeutic algorithm 
based on scientific evidence, including recommendations 
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on disease-modifying drugs recently or undergoing approv-
al processes. The analysis on the risk-benefit profile of each 
drug takes into consideration the efficacy and safety of the 
compound and the specific characteristics of Latin American 
patients (high prevalence of tuberculosis and HTLV). This 
work took into consideration monitoring through pharma-
covigilance programs and recommended wide access to all 
available treatments. The panel proposed that a supranation-
al pharmacovigilance database should be created, with the 
aim of enabling wide-ranging data gathering and, hence, fast 
decision-making in the future, based on experience. 
COMMENTS FROM EXPERTS
RRMS treatment in Latin America must take into con-
sideration the epidemiological characteristics of patients 
from this region, as well as the political and administrative 
circumstances that affect therapeutic decisions. These is-
sues include the high prevalence of HTLV and tuberculosis, 
the fact that some countries lack approval for widely used 
drugs in other countries, the introduction of generic medica-
tions, and the degree of expenditure coverage by the health 
systems. For some countries in which the patient population 
undergoing treatment is small, joint work by regional forums 
enables optimization of clinical experience, access to phar-
macovigilance data, and knowledge on the disease, thus ul-
timately resulting in better clinical practices based upon the 
latest available scientific evidence.
PERSPECTIVES FOR THE NEXT FIVE YEARS
The first oral treatment for MS (Fingolimod) was re-
cently approved by the FDA (USA) in September 2010 and 
by the European Medicines Agency (EMA) in January 2011. 
Nonetheless, until a time is reached when more data re-
garding long-term safety are available, it is likely that dif-
ferent formulations of interferon-beta and Glatiramer 
Acetate will continue to be the preferred first-line treat-
ments for patients with less active MS. The extension of 
Natalizumab treatment beyond two years will possibly de-
pend on evidence of usefulness in JC virus detection assays. 
This may be of prognostic value in relation to the likelihood 
of developing PML, but the availability of this assay in Latin 
America also has to be taken into consideration. Phase III 
trials were recently concluded for cladribine, and the results 
led to treatment rejection for MS by the FDA. The thera-
peutic panorama may also be modified through approval of 
other drugs for MS, which currently under phase III clini-
cal investigations include Alemtuzumab, Teriflunomide, 
Laquinimod, BG-12, Daclizumab and pegylated IFN β-1a. 
CONCLUSIONS
Diagnostic and therapeutic aspects of MS in Latin 
America differ from those used in Europe and in the United 
States due to several aspects, including epidemiological, 
economical, and sanitation factors. The availability and cov-
erage of drug-related expenditure by the public healthcare 
systems are not uniform. The Forum recommended that all 
medication currently approved for treatment of MS needs 
to be available for Latin American patients, independently 
of their economic and social conditions. Results from this 
Forum might ultimately be used by physicians and health 
care authorities, while discussing drug availability in Latin 
American countries. Finally, a supranational database 
should be created to enable retrieval of long-term pharma-
covigilance data from the region.
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